If you ever built a line following robot, you’ll be nostalgic about [Jeremy’s] light-seeking robot. It is a very simple build since there is no CPU and, therefore, also no software. The trick, of ...

The city of Akron has offered to pay to repair a woman's broken sewer line following an impassioned appearance before Akron City Council that brought the meeting to a temporary halt. Overlook Drive ...

Feel free to surprise us, Samsung, but this BB-8-like rolling robot buddy is a CES ghost story. Feel free to surprise us, Samsung, but this BB-8-like rolling robot buddy is a CES ghost story. is a ...

In brief: Zeroth, a startup pushing the boundaries between consumer robotics and artificial intelligence, is introducing two personal robots to the US market. The company's new models, the W1 and M1, ...

CES 2026, the annual consumer tech conference held in Las Vegas, is here. And lucky for you, we have TechCrunch editors and reporters on the ground to cover the news, scout out the interesting, weird, ...

The company’s vision for a “zero labor home” sounds convenient in a dystopian sort of way. The company’s vision for a “zero labor home” sounds convenient in a dystopian sort of way. is the Verge’s ...

Jackery has just pulled the wraps off its newest portable power station, the Explorer 1500 Ultra, and it’s aiming squarely at people who actually use these things outside – not just those who keep ...

An 8-sensor LDR line following robot using ESP32 with dual-threshold hysteresis algorithm. The project includes both Arduino IDE and ESP-IDF development environments, plus threshold calibration tools.

iRobot, the maker of the Roomba vacuum cleaner, filed for bankruptcy protection on Sunday and is pursuing a buyout from its primary manufacturer in China after the company's acquisition by Amazon was ...

Charles Schwab’s CEO Rick Wurster sat down with The Wall Street Journal to discuss prediction markets, young investors and how he views the Trump accounts. Photo: Daniel Vergara When it comes to ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. The current standard of care for the ...